WallStreetZenWallStreetZen

NASDAQ: GRTS
Gritstone Bio Inc Stock

$0.84-0.08 (-8.7%)
Updated Apr 12, 2024
GRTS Price
$0.84
Fair Value Price
-$0.55
Market Cap
$82.47M
52 Week Low
$0.83
52 Week High
$3.33
P/E
-0.7x
P/B
1.59x
P/S
14.42x
PEG
N/A
Dividend Yield
N/A
Revenue
$16.34M
Earnings
-$138.49M
Gross Margin
100%
Operating Margin
-822.65%
Profit Margin
-847.3%
Debt to Equity
2.43
Operating Cash Flow
-$122M
Beta
1.42
Next Earnings
May 9, 2024
Ex-Dividend
N/A
Next Dividend
N/A

GRTS Overview

Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.

Zen Score

Industry Average (23)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how GRTS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

GRTS ($0.84) is overvalued by 252.07% relative to our estimate of its Fair Value price of -$0.55 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
GRTS ($0.84) is not significantly undervalued (252.07%) relative to our estimate of its Fair Value price of -$0.55 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
GRTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more GRTS due diligence checks available for Premium users.

Be the first to know about important GRTS news, forecast changes, insider trades & much more!

GRTS News

Valuation

GRTS fair value

Fair Value of GRTS stock based on Discounted Cash Flow (DCF)
Price
$0.84
Fair Value
-$0.55
Undervalued by
251.88%
GRTS ($0.84) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
GRTS ($0.84) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
GRTS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

GRTS price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-0.7x
Industry
14.72x
Market
42.64x

GRTS price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.59x
Industry
5.93x
GRTS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

GRTS's financial health

Profit margin

Revenue
$10.4M
Net Income
-$30.8M
Profit Margin
-296.8%
GRTS's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
GRTS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$177.8M
Liabilities
$125.9M
Debt to equity
2.43
GRTS's short-term assets ($87.44M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
GRTS's long-term liabilities ($98.58M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
GRTS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
GRTS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$19.5M
Investing
$38.3M
Financing
$15.7M
GRTS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

GRTS vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
GRTS$82.47M-8.79%-0.70x1.59x
LVTX$82.28M-6.29%-1.83x1.48x
LPTX$82.94M+4.01%-0.81x1.38x
RLYB$83.19M-26.17%-1.20x0.78x
CVM$81.67M-1.81%-2.36x6.46x

Gritstone Bio Stock FAQ

What is Gritstone Bio's quote symbol?

(NASDAQ: GRTS) Gritstone Bio trades on the NASDAQ under the ticker symbol GRTS. Gritstone Bio stock quotes can also be displayed as NASDAQ: GRTS.

If you're new to stock investing, here's how to buy Gritstone Bio stock.

What is the 52 week high and low for Gritstone Bio (NASDAQ: GRTS)?

(NASDAQ: GRTS) Gritstone Bio's 52-week high was $3.33, and its 52-week low was $0.83. It is currently -74.74% from its 52-week high and 1.57% from its 52-week low.

How much is Gritstone Bio stock worth today?

(NASDAQ: GRTS) Gritstone Bio currently has 98,065,594 outstanding shares. With Gritstone Bio stock trading at $0.84 per share, the total value of Gritstone Bio stock (market capitalization) is $82.47M.

Gritstone Bio stock was originally listed at a price of $14.24 in Sep 28, 2018. If you had invested in Gritstone Bio stock at $14.24, your return over the last 5 years would have been -94.09%, for an annualized return of -43.21% (not including any dividends or dividend reinvestments).

How much is Gritstone Bio's stock price per share?

(NASDAQ: GRTS) Gritstone Bio stock price per share is $0.84 today (as of Apr 12, 2024).

What is Gritstone Bio's Market Cap?

(NASDAQ: GRTS) Gritstone Bio's market cap is $82.47M, as of Apr 14, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Gritstone Bio's market cap is calculated by multiplying GRTS's current stock price of $0.84 by GRTS's total outstanding shares of 98,065,594.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.